Primary outcomeMean· Baseline
Quality of Life Questionnaire for Cancer Patients Treated With Anticancer Drugs (QOL-ACD) Total and Subscale Score at Baseline
| Group | Value (units on a scale) | Spread |
|---|---|---|
| Leuprorelin Acetate | 88.9 | 11.11 |
Trial · Observational
CompletedPhase not statedResults postedRegistry dataLeuplin SR 11.25 mg Injection Kit Specified Drug-use Survey: "QOL Survey in Premenopausal Breast Cancer Patients"
Overview
- Status
- Completed
- Phase
- Phase not stated
- Enrollment
- 2,816 participants (actual)
- Sponsor
- Takeda · Industry
- Design
- Not stated
- Countries
- Not stated
- Start
- Sept 2011
- Primary completion
- Mar 2015
- Completion
- Mar 2015
- First posted
- 9 May 2014 (estimated)
- Last update posted
- 18 Oct 2016 (estimated)
- Conditions
- Breast Cancer
Timeline
1 trial · 1 completed · 1 with posted results
- Completed
- Ongoing
- Not yet recruiting
- Stopped
- Estimated dates (est.)
- Results posted
201120122013201420152016
- Ph –
Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey: "QOL Survey in Premenopausal Breast Cancer Patients"
NCT02134977Sept 2011 to Mar 2015
Registry summary
Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.
The purpose of this survey is to examine the effect on quality of life (QOL) improvement and convenience of switching to leuprorelin acetate 3 months depot 11.25 milligram (mg) injection kit (Leuplin SR 11.25 mg injection kit) from a 4-week adjuvant therapy with a luteinizing hormone-releasing hormone analog (LH-RHa) 1 month depot over 48 weeks in premenopausal breast cancer participants in daily medical practice. Influence of condition of estrogen receptor expression on the efficacy and safety of leuprorelin acetate SR 11.25 mg injection kit was also evaluated.
Interventions
- Leuprorelin AcetateDrug
Arms1
Other
Leuprorelin Acetate
Subcutaneous administration of leuprorelin acetate 11.25 mg once every 12 weeks
Primary outcomes9
Outcomes the sponsor listed as primary.
Quality of Life Questionnaire for Cancer Patients Treated With Anticancer Drugs (QOL-ACD) Total and Subscale Score at Baseline
Time frame · Baseline
Registry description
QOL-ACD score is a score used for cancer participants treated with anti-cancer drug and is a 22-item self-reported instrument assessing differences in symptom severity and health-related QOL. It includes 4 subscale domains: Daily Activities, Physical Condition, Social Activities, Mental and Psychological Status. Total and subscale scores are calculated as sum of items within each subscale: Daily Activity (items 1-6), Physical Condition (7-11), Psychological Condition (12-16), Social Attitude (17-21) and total (1-22). Face scale: 5-point score for 1 item (22). Participants answer each question on a 5-point scale (1: not at all \[worst response\] to 5: very much \[best response\]). Score range for total score is 22 to 110 and subscale score range for daily activity is 6 to 30, and for physical condition, psychological condition, and social attitude is 5 to 25. Less total/subscale scores reflect greater symptom severity and symptom impact on health-related QOL.
QOL-ACD Total and Subscale Score at Week 12
Time frame · Week 12
Registry description
QOL-ACD score is a score used for cancer participants treated with anti-cancer drug and is a 22-item self-reported instrument assessing differences in symptom severity and health-related QOL. It includes 4 subscale domains: Daily Activities, Physical Condition, Social Activities, Mental and Psychological Status. Total and subscale scores are calculated as sum of items within each subscale: Daily Activity (items 1-6), Physical Condition (7-11), Psychological Condition (12-16), Social Attitude (17-21) and total (1-22). Face scale:5-point score for 1 item (22). Participants answer each question on a 5-point scale (1: not at all \[worst response\] to 5: very much \[best response\]). Score range for total score is 22 to 110 and subscale score range for daily activity is 6 to 30, and for physical condition, psychological condition, and social attitude is 5 to 25. Less total/subscale scores reflect greater symptom severity and symptom impact on health-related QOL.
QOL-ACD Total and Subscale Score at Week 48
Time frame · Week 48
Registry description
QOL-ACD score is a score used for cancer participants treated with anti-cancer drug and is a 22-item self-reported instrument assessing differences in symptom severity and health-related QOL. It includes 4 subscale domains: Daily Activities, Physical Condition, Social Activities, Mental and Psychological Status. Total and subscale scores are calculated as sum of items within each subscale: Daily Activity (items 1-6), Physical Condition (7-11), Psychological Condition (12-16), Social Attitude (17-21) and total (1-22). Face scale: 5-point score for 1 item (22). Participants answer each question on a 5-point scale (1: not at all \[worst response\] to 5: very much \[best response\]). Score range for total score is 22 to 110 and subscale score range for daily activity is 6 to 30, and for physical condition, psychological condition, and social attitude is 5 to 25. Less total/subscale scores reflect greater symptom severity and symptom impact on health-related QOL.
QOL-ACD Breast (QOL-ACD-B) Score at Baseline
Time frame · Baseline
Registry description
QOL-ACD-B is a part of QOL-ACD (using questionnaire items 1 to 18). QOL-ACD is a score used for cancer participants treated with anti-cancer drug and is a 22-item self-reported instrument assessing differences in symptom severity and health-related QOL. Participants answer each question on a 5-point scale (1: not at all \[worst response\] to 5: very much \[best response\]). Total score was calculated over score range 0-100 for item 1 to 18 as ((a sum of 18 items)/18-1)\*25). Score for physical condition and pain was calculated over score range 0-100 for item 1 to 6 as ((a sum of 6 items)/6-1)\*25)). Score for health-care and illness satisfaction was calculated over score range 0-100 for item 7 to 10 as ((a sum of 4 items)/4-1)\*25)), where less scores reflect greater symptom severity and symptom impact on health-related quality of life. Means and standard deviations were calculated for the total score and score of each subscale from questionnaire items 1 to 18.
Score of QOL-ACD-B at Week 12
Time frame · Week 12
Registry description
QOL-ACD-B is a part of QOL-ACD (using questionnaire items 1 to 18). QOL-ACD is a score used for cancer participants treated with anti-cancer drug and is a 22-item self-reported instrument assessing differences in symptom severity and health-related QOL. Participants answer each question on a 5-point scale (1: not at all \[worst response\] to 5: very much \[best response\]). Total score for QOL-ACD-B is calculated as a sum of 18 items, score range: 18 to 90 where less scores reflect greater symptom severity and symptom impact on health-related quality of life. Means and standard deviations were calculated for the total score and score of each subscale from questionnaire items 1 to 18.
Score of QOL-ACD-B at Week 48
Time frame · Week 48
Registry description
QOL-ACD-B is a part of QOL-ACD (using questionnaire items 1 to 18). QOL-ACD is a score used for cancer participants treated with anti-cancer drug and is a 22-item self-reported instrument assessing differences in symptom severity and health-related QOL. Participants answer each question on a 5-point scale (1: not at all \[worst response\] to 5: very much \[best response\]). Total score for QOL-ACD-B is calculated as a sum of 18 items, score range: 18 to 90 where less scores reflect greater symptom severity and symptom impact on health-related quality of life. Means and standard deviations were calculated for the total score and score of each subscale from questionnaire items 1 to 18.
Score of QOL-ACD-B Items 19, 20 and 21 at Baseline
Time frame · Baseline
Registry description
QOL-ACD-B is a part of QOL-ACD (using questionnaire items 1 to 18). For questionnaire item 19 (Did you feel inferior to your child when you interact with him/her? \[due to the impact of illness and treatment\]), item 20 (Did you worry about child rearing? \[due to the impact of illness and treatment\]), and item 21 (Do you worry about pregnancy or delivery? \[due to the impact of illness and treatment\]), the calculation was based on the score of each item. Each item was scored on a 5-point scale, where 1 was the worst response and 5 was the best.
Score of QOL-ACD-B Items 19, 20 and 21 at Week 12
Time frame · Week 12
Registry description
QOL-ACD-B is a part of QOL-ACD (using questionnaire items 1 to 18). For questionnaire item 19 (Did you feel inferior to your child when you interact with him/her? \[due to the impact of illness and treatment\]), item 20 (Did you worry about child rearing? \[due to the impact of illness and treatment\]), and item 21 (Do you worry about pregnancy or delivery? \[due to the impact of illness and treatment\]), the calculation was based on the score of each item. Each item was scored on a 5-point scale, where 1 was the worst response and 5 was the best.
Score of QOL-ACD-B Items 19, 20 and 21 at Week 48
Time frame · Week 48
Registry description
QOL-ACD-B is a part of QOL-ACD (using questionnaire items 1 to 18). For questionnaire item 19 (Did you feel inferior to your child when you interact with him/her? \[due to the impact of illness and treatment\]), item 20 (Did you worry about child rearing? \[due to the impact of illness and treatment\]), and item 21 (Do you worry about pregnancy or delivery? \[due to the impact of illness and treatment\]), the calculation was based on the score of each item. Each item was scored on a 5-point scale, where 1 was the worst response and 5 was the best.
Secondary outcomes(9)
Percentage of Participants With Reduction in Frequency of Medical Visits Due to Change in Medicinal Agents
Time frame · Week 48
Registry description
The question was with regard to the assessment of convenience associated with the changes in agents, "Did the change in agents reduce the frequency of your medical visits?" and the answers were categorized as very much reduced, somewhat reduced, unchanged. Change in medicinal agents means participants with a historical diagnosis of premenopausal breast cancer who switched to leuprorelin acetate sustained-release 11.25 mg injection kit from a 4-week adjuvant therapy with a LH-RHa 1 month depot preparation as part of daily medical practice.
Percentage of Participants Who Felt Relief From Physical and Emotional Burden
Time frame · Week 48
Registry description
The question was with regard to the assessment of convenience associated with the changes in agents, "The change in agents reduced the frequency of injections by one third; for this reason, did you feel relief from physical and emotional burden?" and the answers were categorized as felt extreme relief, felt slight relief, no feeling either way, felt little relief, felt no relief.
Percentage of Participants With Relief From Financial Burden Due to the Change in Medicinal Agents
Time frame · Week 48
Registry description
The question was with regard to the assessment of convenience associated with the changes in agents, "Did you feel relief from financial burden (example, 3 months' drug costs and transportation fee) due to the change in agents?" and the answers were categorized as felt extreme relief, felt slight relief, no feeling either way, felt little relief, felt no relief. The sum of all the categories is not 100% because of rounding error.
Percentage of Participants Who Worried About the Effect of the Medicinal Agent
Time frame · Week 48
Registry description
The question was with regard to the assessment of convenience associated with the changes in agents, "The change in agents reduced the frequency of injections by one third; for this reason, did you worry about the effect?" and the options of the answers were not at all worried, not too worried, no thought either way, somewhat worried, and very worried.
Percentage of Participants With Change in Adverse Drug Reactions Due to the Change in Medicinal Agents
Time frame · Week 48
Registry description
The question was with regard to the assessment of convenience associated with the changes in agents, "Was there a change in adverse drug reactions (e.g., menopausal-like symptoms such as hot flushes, injection-site abnormalities) due to the change in agents?" and the options of the answers were events became much less severe, events became less severe, whether or not the events became severe cannot be determined, events became slightly more severe, and events became very severe.
Percentage of Participants With Change in Pain at the Time of Injection Due to the Change in Medicinal Agents
Time frame · Week 48
Registry description
The question was with regard to the assessment of convenience associated with the changes in agents, "Was there a change in pain at the time of injection due to the change in agents?" and the options of the answers were significantly relieved, slightly relieved, whether or not the pain worsened or was relieved cannot be determined, worsened slightly, and worsened significantly.
Percentage of Participants With Positive Change in Agents
Time frame · Week 48
Registry description
The question was with regard to the assessment of convenience associated with the changes in agents, "Was the change in agents good?" and the options of the answers were very good, somewhat good, whether or not the change in agents was good cannot be determined, somewhat bad, very bad.
Number of Participants Reporting One or More Adverse Drug Reactions
Time frame · Baseline up to Week 48
Registry description
Adverse drug reactions are defined as adverse events (AE) which are in the investigator's opinion of causal relationship to the study treatment. AE are defined as any unfavorable and unintended signs, symptoms or diseases temporally associated with the use of a medicinal product reported from the first dose of study drug to the last dose of study drug.
Number of Participants Reporting One or More Serious Adverse Drug Reactions
Time frame · Baseline up to Week 48
Registry description
Serious adverse drug reactions are defined as serious adverse events (SAE) which are in the investigator's opinion of causal relationship to the study treatment. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The event was occurred in breast cancer female.
Posted results
Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.
Primary outcome results
Primary outcomeMean· Week 12
QOL-ACD Total and Subscale Score at Week 12
| Group | Value (units on a scale) | Spread |
|---|---|---|
| Leuprorelin Acetate | 88.7 | 11.2 |
Primary outcomeMean· Week 48
QOL-ACD Total and Subscale Score at Week 48
| Group | Value (units on a scale) | Spread |
|---|---|---|
| Leuprorelin Acetate | 89.9 | 11.08 |
Primary outcomeMean· Baseline
QOL-ACD Breast (QOL-ACD-B) Score at Baseline
| Group | Value (units on a scale) | Spread |
|---|---|---|
| Leuprorelin Acetate | 70.4 | 13.24 |
Primary outcomeMean· Week 12
Score of QOL-ACD-B at Week 12
| Group | Value (units on a scale) | Spread |
|---|---|---|
| Leuprorelin Acetate | 71.0 | 13.36 |
Primary outcomeMean· Week 48
Score of QOL-ACD-B at Week 48
| Group | Value (units on a scale) | Spread |
|---|---|---|
| Leuprorelin Acetate | 71.9 | 13.50 |
Primary outcomeMean· Baseline
Score of QOL-ACD-B Items 19, 20 and 21 at Baseline
| Group | Value (units on a scale) | Spread |
|---|---|---|
| Leuprorelin Acetate | 3.3 | 1.40 |
Primary outcomeMean· Week 12
Score of QOL-ACD-B Items 19, 20 and 21 at Week 12
| Group | Value (units on a scale) | Spread |
|---|---|---|
| Leuprorelin Acetate | 3.5 | 1.35 |
Adverse events, as posted
| Group | Deaths | Serious events | Other events |
|---|---|---|---|
| Leuprorelin AcetateLeuprorelin Acetate, 11.25 mg sustained-release injection, subcutaneously, once every 12 weeks as part of daily medical practice were observed for up to 48 weeks. | – | 8 / 2714 | 239 / 2714 |
Each cell reads participants affected / participants at risk, as the registry posted them.
Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works
Studies0
Studies that cite this trial.
No study cites this trial.
Eligibility
Who could join, as posted.
- Sex
- Female
- Age
- Not stated
- Healthy volunteers
- Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria:
* Premenopausal breast cancer participants who meet all the following criteria are to be enrolled in the surveillance:
1. Participants who received 4 weeks of treatment with a repository LH-RHa preparation within 1 week prior to administration of Leuplin SR 11.25 mg Injection Kit.
2. Participants receiving Leuplin SR 11.25 mg Injection Kit as adjuvant therapy.
3. Participants with performance status grade of 0 or 1.
4. Participants who answered all of the questions on the "QOL check sheet (I)" at the start (Week 0) of treatment with Leuplin SR 11.25 mg Injection Kit.
Exclusion Criteria:
* Participants who meet any of the following criteria are to be excluded from the surveillance:
1. Participants with a history of hypersensitivity to ingredient(s) in Leuplin SR 11.25 mg Injection Kit or synthetic derivatives of luteinizing hormone-releasing hormone (LH-RH) or LH-RH.
2. Pregnant women, possibly pregnant women, and nursing mothers.
3. Participants with advanced (T4 or M1 according to the TNM classification \[General Rules for Clinical and Pathological Recording of Breast Cancer: 16th edition\]) or recurrent breast cancer.
PepBank is a research reference. Talk to a doctor before you use any peptide.